| 1.11 -0.005 (-0.45%) | 10-04 10:40 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.33 | 1-year : | 1.42 |
| Resists | First : | 1.14 | Second : | 1.22 |
| Pivot price | 1.12 |
|||
| Supports | First : | 1.01 | Second : | 0.84 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.12  |
| MA(100) : | 1.11 |
MA(250) : | 1.19 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 43.4 |
| RSI | RSI(14): 50.3 | |||
| 52-week | High : | 2.4 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FEMY ] has closed above bottom band by 37.6%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 1.1 - 1.1 | 1.1 - 1.11 |
| Close: | 1.1 - 1.12 | 1.12 - 1.13 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Wed, 18 Sep 2024
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
Wed, 11 Sep 2024
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Tue, 10 Sep 2024
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Mon, 09 Sep 2024
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Thu, 29 Aug 2024
Femasys gains European and Canadian approval for FemVue MINI - Investing.com
Thu, 29 Aug 2024
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 2.001e+007 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 543 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.612e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 23.6 % |
| Return on Equity (ttm) | -59.6 % |
| Qtrly Rev. Growth | 950100 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 15.63 |
| Price to Cash Flow | -6.15 |
| Dividend | 0 |
| Forward Dividend | 684720 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|